Monitor Tempus (TEM) stock price as it determines actual consideration for PSNL holders. Key milestones: filing of S-4, stockholder vote, and HSR clearance. If TEM stays above $48.42, PSNL holders benefit from stock upside; if it falls below $46, PSNL can walk away. The deal appears well-structured with Merck support, but regulatory risk remains.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 21 $13.44entry
- T+1 · 4mo ago −7.22%α −7.10% · $12.47
- T+5 · 4mo ago −10.86%α −9.63% · $11.98
- T+20 · 3mo ago +3.50%α +0.94% · $13.91
- T+60 · 5w ago +17.93%α +13.96% · $15.85
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Personalis (PSNL) entered into a definitive merger agreement with Tempus AI (TEM) on July 20, 2026. PSNL shareholders will receive $16.25 per share in Tempus stock (variable exchange ratio, floored at 0.3356 if TEM ≤ $48.42), with Tempus having the option to pay cash for up to 50% of shares. Merck, holding ~13% of PSNL, has agreed to vote in favor. The deal is expected to close in late 2026 or early 2027, subject to stockholder approval, HSR clearance, and other conditions.
Key Financial Metrics
Key Facts
- Definitive merger agreement with Tempus AI: PSNL shareholders receive $16.25 per share in Tempus stock (exchange ratio variable with floor of 0.3356).
- Tempus may elect to pay cash for up to 50% of outstanding PSNL shares at $16.25 per share.
- Merck (~13% holder) entered into a voting agreement to support the deal.
- Mutual termination fee of approximately $76.8 million each way.
- PSNL has the right to terminate if Tempus stock price falls below $46.00 (Lower Floor Price).
- Closing conditions include stockholder approval, HSR clearance, S-4 effectiveness, and tax opinion.
Financial Impact
Consideration valued at $16.25 per share (~6% premium to prior close, 28% premium to 30-day VWAP per prior analysis); total enterprise value ~$1.5B.
Risk Factors
- Stockholder approval may fail (though Merck's 13% vote helps).
- Antitrust (HSR) clearance could be delayed or blocked.
- Tempus stock price decline below $46 could lead to PSNL termination.
- Integration risk and potential business disruption post-close.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-309106 |
| Document: 0001193125-26-309106-index-headers.html | 0001193125-26-309106 |
| Document: 0001193125-26-309106-index.html | 0001193125-26-309106 |
| Document: 0001193125-26-309106.txt | 0001193125-26-309106 |
Track record
29 reports on PSNL
3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +18.82% at T+60 after the Jul 20, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.16 Now $14.80 −2.34% settles Feb 12
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $15.71 Now $14.80 −5.79% settles Feb 11
- Nov 12, 20264d ago 425 Neutral 4/10 Entry $15.86 Now $14.80 −6.68% settles Feb 10
- Nov 6, 202610d ago 425 Neutral 3/10 Entry $15.95 Now $14.80 −7.21% settles Feb 5
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $15.55 Now $14.80 −4.82% settles Feb 3
- Nov 3, 202613d ago 425 Neutral 3/10 Entry $15.79 Now $14.80 −6.27% settles Feb 2
- Oct 30, 202617d ago 425 Neutral 4/10 Entry $15.76 Now $14.80 −6.09% settles Jan 29
- Oct 21, 202626d ago DEFM14A Neutral 5/10 Entry $15.82 Now $14.80 −6.45% settles Jan 20
- Oct 20, 202627d ago 425 Neutral 4/10 Entry $15.90 Now $14.80 −6.92% settles Jan 19
- Oct 20, 202627d ago 425 Neutral 5/10 Entry $15.90 Now $14.80 −6.92% settles Jan 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers